Alvimopan, a selective peripherally acting μ-opioid antagonist

Neurogastroenterology and Motility

Volumn 17, Issue 2, 2005, Pages 157-165

  Camilleri, Michael ^a,b  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Constipation; Gastrointestinal transit; Ileus; Irritable bowel

Indexed keywords

17 METHYLNALTREXONE; 2 METHYLSEROTONIN; ACETORPHAN; ACTIVATED CARBON; ADL 080011; ALVIMOPAN; BRADYKININ; CASTOR OIL; CODEINE; DRUG METABOLITE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; LAXATIVE; LOPERAMIDE; MORPHINE; MORPHINE SULFATE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR ANTAGONIST; NALOXONE; NEOSTIGMINE; OPIATE RECEPTOR; PLACEBO; SEROTONIN 4 AGONIST; TEGASEROD; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ANIMAL EXPERIMENT; ANTINOCICEPTION; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DOG; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; ENDOCYTOSIS; FECES; GASTROINTESTINAL MOTILITY; GUINEA PIG; HUMAN; HUMAN EXPERIMENT; ILEUS; INTERSTITIAL CELL OF CAJAL; INTESTINE TRANSIT TIME; IRRITABLE COLON; MAJOR CLINICAL STUDY; META ANALYSIS; MOUSE; NAUSEA; NONHUMAN; NORMAL HUMAN; PERISTALSIS; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; POSTOPERATIVE ILEUS; PRIORITY JOURNAL; QT INTERVAL; RABBIT; RAT; REVIEW; SENSORY NERVE; SYSTEMATIC REVIEW; VAGOTOMY; VOLUNTEER; VOMITING;

ANIMALS; CONSTIPATION; GASTROINTESTINAL MOTILITY; HUMANS; ILEUS; NARCOTIC ANTAGONISTS; PIPERIDINES; POSTOPERATIVE COMPLICATIONS; RECEPTORS, OPIOID, MU;

EID: 16444366557     PISSN: 13501925     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2005.00640.x     Document Type: Review

References (56)

1. Prado D, Global Adult Racedotril Study Group. A multi-national comparison of racecadotril and loperamide in the treatment of acute watery diarrhoea in adults. Scand J Gastroenterol 2002; 37: 656-61.
2. Salazar-Lindo E, Santisteban-Ponce J, Chea-Woo E, Gutierrez M. Racedotril in the treatment of acute watery diarrhea in children. N Engl J Med 2000; 343: 463-7.
3. Bagnol D, Mansour A, Akil H, Watson SJ. Cellular localization and distribution of the cloned mu and kappa-opioid receptors in rat gastrointestinal tract. Neuroscience 1997; 81: 579-91.
4. Pickel J, Bagnol D, Watson SJ, Akil H. Opioid receptor expression in the rat gastrointestinal tract: a quantitative study with comparison to the brain. Mol Brain Res 1997; 46: 1-8.
5. Sternini C, Patierno S, Selmer I-S, Kirchgessner A. The-opioid system in the gastrointestinal tract. Neurogastroenterol Mot 2004; 16 (Suppl. 2): 3-16.
6. Wood JD, Galligan JJ. Function of-opioids in the enteric nervous system. Neurogastroenterol Motil 2004; 16 (Suppl. 2): 17-28.
7. Grundy D, Booth CE, Winchester W, Hicks GA. Peripheral opiate action on afferent fibres supplying the rat intestine. Neurogastroenterol Mot 2004; 16 (Suppl. 2): 29-37.
8. Greenwood-Van Meerveld B, Gardner CJ, Little PJ, Hicks GA, Dehaven-Hudkins DL. Preclinical studies of-opioids and-opioid antagonists on gastrointestinal function. Neurogastroenterol Mot 2004; 16 (Suppl. 2): 46-53.
9. Long SL, Little PJ, Gaul F, Guo D, Koblish M, DeHaven-Hudkins DL. Effects of novel μ-opioid antagonists on gastrointestinal (GI) transit in mice. Soc Neurosci Abstr 1999; 25: 1706.
10. Little PJ, Koblish M, DeHaven-Hudkins DL, Pietras MR, Cowan A. ADL 8-2698, a GI restricted-opioid antagonist, blocks the antisecretory and colorectal transit effects of morphine and loperamide. Soc Neurosci Abstr 2001; 27: 907.2.
11. Holzer P. Opioids and-opioid receptors in the enteric nervous system: from a problem in-opioid analgesia to a possible new prokinetic therapy in humans. Neurosci Lett 2004; 361: 192-5.
12. Lembo T, Naliboff BD, Matin K et al. Irritable bowel syndrome patients show altered sensitivity to exogenous-opioids. Pain 2000; 87: 137-47.
13. Delgado-Aros S, Chial HJ, Camilleri M et al. Effects of a kappa-opioid agonist, asimadoline, on satiation and gastrointestinal motor and sensory functions in humans. Am J Physiol 2003; 284: G558-66.
14. Borody TJ, Quigley EM, Phillips SF et al. Effects of morphine and atropine on motility and transit in the human ileum. Gastroenterology 1985; 89: 562-70.
15. Steadman CJ, Phillips SF, Camilleri M, Talley NJ, Haddad A, Hanson R. Control of muscle tone in the human colon. Gut 1992; 33: 541-6.
16. Kaufman PN, Krevsky B, Malmud LS et al. Role of opiate receptors in the regulation of colonic transit. Gastroenterology 1988; 94: 1351-6.
17. Stacher G, Steinringer H, Schneider C, et al. Effects of the prodrug loperamide oxide, loperamide, and placebo on jejunal motor activity. Dig Dis Sci 1992; 37: 198-204.
18. Cann PA, Read NW, Holdsworth CD, Barends D. Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig Dis Sci 1984; 29: 239-47.
19. Sun WM, Read NW, Verlinden M. Effects of loperamide oxide on gastrointestinal transit time and anorectal function in patients with chronic diarrhoea and faecal incontinence. Scand J Gastroenterol 1997; 32: 34-8.
20. Camilleri M, Malagelada JR, Stanghellini V, Zinsmeister AR, Kao PC, Li CH. Dose-related effects of synthetic human beta-endorphin and naloxone on fed gastrointestinal motility. Am J Physiol 1986; 251: G147-54.
21. Hawkes ND, Rhodes J, Evans BK, Rhodes P, Hawthorne AB, Thomas GA. Naloxone treatment for irritable bowel syndrome- a randomised controlled trial with an oral formulation. Aliment Pharm Ther 2002; 16: 1649-54.
22. Delaney CP. Clinical perspective on postoperative ileus and the effect of opiates. Neurogastroenterol Mot 2004; 16 (Suppl. 2): 61-6.
23. Behm B, Stollman N. Postoperative ileus: etiologies and interventions. Clin Gastroenterol Hepatol 2003; 1: 71-80.
24. Akca O, Doufas AG, Sessler DI. Use of selective opiate receptor inhibitors to prevent postoperative ileus. Minerva Anestesiol 2002; 68: 162-5.
25. Bauer AJ, Boeckxstaens GE. Mechanisms of postoperative ileus. Neurogastroenterol Mot 2004; 16 (Suppl. 2): 54-60.
26. Gomez-Flores R, Rice KC, Zhang X, Weber RJ. Increased tumor necrosis factor-alpha and nitric oxide production by rat macrophages following in vitro stimulation and intravenous administration of the delta-opioid agonist SNC 80. Life Sci 2001; 68: 2675-84.
27. Kowalski J. Augmenting effect of-opioids on nitrite production by stimulated murine macrophages. Neuropeptides 1998; 32: 287-91.
28. Gomez-Flores R, Weber RJ. Immunomodulation of macrophage functions by-opioids. Adv Exp Med Biol 1998; 437: 13-9.
29. Narayan P, Singh VK, Agarwal SS et al. Immunomodulation by-opioid peptidomimetic compound. Neuroimmunomodulation 2001; 9: 134-40.
30. Kalff JC, Schraut WH, Billiar TR, Simmons RL, Bauer AJ. Roles of inducible nitric oxide synthase in postoperative intestinal smooth muscle dysfunction in rodents. Gastroenterology 1999; 188: 316-27.
31. Wei G, Moss J, Yuan CS. Opioid-induced immunosuppression: is it centrally mediated or peripherally mediated? Biochem Pharmacol 2003; 65: 1761-6.
32. Kalff JC, Schraut WH, Simmons R, Bauer AJ. Surgical manipulation of the gut elicits an intestinal muscularis inflammatory response resulting in postoperative ileus. Ann Surg 1998; 228: 652-63.
33. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003; 63: 649-71.
34. De Luca A, Coupar IM. Insights into-opioid action in the intestinal tract. Pharmacol Therapeut 1996; 69: 103-15.
35. Pappagallo M. Incidence, prevalence, and management of-opioid bowel dysfunction. Am J Surg 2001; 182: 11-8S.
36. Meissner W, Schmidt U, Hartmann M, Kath R, Reinhart K. Oral naloxone reverses-opioid-associated constipation. Pain 2000; 84: 105-9.
37. Yuan CS, Foss JF, O'Connor M et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA 2000; 283: 367-72.
38. Yuan CS, Foss JF, O'Connor M et al. Effects of enteric-coated methylnaltrexone in preventing-opioid-induced delay in oral-cecal transit time. Clinical Pharmacol Therapeut 2000; 67: 398-404.
39. Schmidt WK. Alvimopan* (ADL 8-2698) is a novel peripheral-opioid antagonist. Am J Surg 2001; 182: 27-38S.
40. Zimmerman DM, Gidda JS, Cantrell BE, Schoepp DD, Johnson BG, Leander JD. Discovery of a potent, peripherally selective truns-3,4-dimethyl-4-(3- hydroxyphenyl)piperidine-opioid antagonist for the treatment of gastrointestinal motility disorders. J Med Chem 1994; 37: 2262-5.
41. Evans DC, Jacobs J, Johnson BG et al. LY246736: a selective antagonist for peripheral μ-opioid receptors. Gastroenterology 1994; 106: A495.
42. 35S]GTPγS binding by ADL 8-2698, a potent-opioid receptor antagonist. Soc Neurosci Abstr 2000; 26: 635.
43. Callaghan JT, Cerimele B, Nowak TV, DeLong A, Nyhart E, Oldham S. Effect of the-opioid antagonist LY246736 on gastrointestinal transit in human subjects. Gastroenterology 1998; 114: G3015.
44. Barr WH, Nguyen P, Slattery M, Russell R, Carpenter RL. ADL 8-2698 reverses-opioid induced delay in colonic transit. Clin Pharmacol Therapeut 2000; 67: 91.
45. Liu SS, Hodgson PS, Carpenter RL, Fricke JR Jr. ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia. Clin Pharmacol Therapeut 2001; 69: 66-71.
46. Fricke JR, Lindquist D, Carpenter RL. ADL 8-2698 does not antagonize-opioid analgesia. Clin Pharmacol Therapeut 2000; 67: 93.
47. Hodgson PS, Liu SS, Carpenter RL. ADL 8-2698 prevents morphine inhibition of GI transit. Clin Pharmacol Therapeut 2000; 67: 93.
48. Hasson AL, Donovick R, Ling W, Carpenter R, Rawson RA, George D. Reversal of-opioid-induced gastrointestinal dysfunction in patients receiving chronic-opioid therapy using ADL 8-2698 a μ-opioid antagonist. Drug Alcohol Depend 2001; 63: S63-4.
49. Liberto JG, Herschler JA, Jaffe JH, Norbeck JH, Carpenter RL. Effects of ADL 8-2698, a peripherally restricted mu-opioid antagonist, on gut motility in methadone and LAAM-dependent patients with-opioid-induced constipation: a dose-ranging study. Drug Alcohol Depend 2001; 63: S91.
50. Little PJ, Koblish M, DeHaven-Hudkins DL, Pietras MR, Cowan A. ADL 8-2698, a GI restricted-opioid antagonist, blocks the antisecretory and colorectal transit effects of morphine and loperamide. Soc Neurosci Abstr 2001; 27: 907.
51. Taguchi A, Sharma N, Saleem RM et al. Selective postoperative inhibition of gastrointestinal-opioid receptors. N Engl J Med 2001; 345: 935-40.
52. Wolff BG, Michelassi F, Gerkin T et al. Alvimopan, a novel, peripherally acting μ-opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus. Ann Surg 2004; 240: 728-35.
53. Vassallo M, Camilleri M, Phillips SF, Brown ML, Chapman NJ, Thomforde GM. Transit through the proximal colon influences stool weight in the irritable bowel syndrome. Gastroenterology 1992; 102: 102-8.
54. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde GM. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000; 118: 463-8.
55. Muller-Lissner SA, Fumagalli I, Bardhan KD et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001; 15: 1655-66.
56. Garnett W, Kelleher DL, Hickmott F et al. Alvimopan (ALV) shortens whole bowel transit time in adults with chronic constipation (CC). Gastroenterology 2004; 126: A643.